CXCL8 and myeloid sarcoma: In the AQP4+ NMOSD cohort compared to MS patients, 31 analytes were significantly different compared to MS: IP-10, SDF-1α, IL-8, TWEAK, MCP-1, MIP-1β, CD30, TNFR2, IL-18, APRIL, GRO-α, IL-16, HGF, SCF, MDC, Fractalkine, MIP-3α, IL-2R, MCP-2, TRAIL, Eotaxin-2, MIG, IL-1α, IL-7, ENA-78, IL-21, IL-3, M-CSF, CD40L, MMP-1, IL-22, with all being higher in AQP4+ NMOSD, except for IL-16 (Figures 1C, D; Supplementary Figure 1).